drugset / Trial / NCT06892639

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

NCT06892639 ↗

Phase 3 Active not recruiting 32 enrolled Castle Creek Biosciences, LLC. Prosoft Clinical · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.

Timeline

Start
2025-03-27
Primary completion
2027-09
Completion
2042-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabocemagene Autoficel Cell therapy — Intrathecal